434 related articles for article (PubMed ID: 19581523)
41. C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)--endogenous negative regulators of Src-family protein kinases.
Chong YP; Mulhern TD; Cheng HC
Growth Factors; 2005 Sep; 23(3):233-44. PubMed ID: 16243715
[TBL] [Abstract][Full Text] [Related]
42. SRC: a century of science brought to the clinic.
Aleshin A; Finn RS
Neoplasia; 2010 Aug; 12(8):599-607. PubMed ID: 20689754
[TBL] [Abstract][Full Text] [Related]
43. Src-family Protein Tyrosine Kinases: A promising target for treating Cardiovascular Diseases.
Zhai Y; Yang J; Zhang J; Yang J; Li Q; Zheng T
Int J Med Sci; 2021; 18(5):1216-1224. PubMed ID: 33526983
[TBL] [Abstract][Full Text] [Related]
44. Src-family protein tyrosine kinases: A promising target for treating chronic pain.
Ge MM; Zhou YQ; Tian XB; Manyande A; Tian YK; Ye DW; Yang H
Biomed Pharmacother; 2020 May; 125():110017. PubMed ID: 32106384
[TBL] [Abstract][Full Text] [Related]
45. SRC inhibitors as potential therapeutic agents for human cancers.
Trevino JG; Summy JM; Gallick GE
Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
[TBL] [Abstract][Full Text] [Related]
46. Src family kinases in chronic kidney disease.
Wang J; Zhuang S
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F721-F728. PubMed ID: 28615246
[TBL] [Abstract][Full Text] [Related]
47. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis.
Silva CM
Oncogene; 2004 Oct; 23(48):8017-23. PubMed ID: 15489919
[TBL] [Abstract][Full Text] [Related]
48. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
[TBL] [Abstract][Full Text] [Related]
49. Synthetic SRC-kinase domain inhibitors and their structural requirements.
Schenone S; Manetti F; Botta M
Anticancer Agents Med Chem; 2007 Nov; 7(6):660-80. PubMed ID: 18045061
[TBL] [Abstract][Full Text] [Related]
50. Src signaling in cancer invasion.
Guarino M
J Cell Physiol; 2010 Apr; 223(1):14-26. PubMed ID: 20049846
[TBL] [Abstract][Full Text] [Related]
51. A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity.
Chong YP; Mulhern TD; Zhu HJ; Fujita DJ; Bjorge JD; Tantiongco JP; Sotirellis N; Lio DS; Scholz G; Cheng HC
J Biol Chem; 2004 May; 279(20):20752-66. PubMed ID: 14985335
[TBL] [Abstract][Full Text] [Related]
52. Emerging role for SRC family kinases in junction dynamics during spermatogenesis.
Xiao X; Yang Y; Mao B; Cheng CY; Ni Y
Reproduction; 2019 Mar; 157(3):R85-R94. PubMed ID: 30608903
[TBL] [Abstract][Full Text] [Related]
53. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?
Chen T; George JA; Taylor CC
Anticancer Drugs; 2006 Feb; 17(2):123-31. PubMed ID: 16428929
[TBL] [Abstract][Full Text] [Related]
54. Src family kinase tyrosine phosphorylates Toll-like receptor 4 to dissociate MyD88 and Mal/Tirap, suppressing LPS-induced inflammatory responses.
Mitchell J; Kim SJ; Seelmann A; Veit B; Shepard B; Im E; Rhee SH
Biochem Pharmacol; 2018 Jan; 147():119-127. PubMed ID: 29175418
[TBL] [Abstract][Full Text] [Related]
55. Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets.
Bußmann L; Hoffer K; von Bargen CM; Droste C; Lange T; Kemmling J; Schröder-Schwarz J; Vu AT; Akingunsade L; Nollau P; Rangarajan S; de Wijn R; Oetting A; Müller C; Böckelmann LC; Zech HB; Berger JC; Möckelmann N; Busch CJ; Böttcher A; Gatzemeier F; Klinghammer K; Simnica D; Binder M; Struve N; Rieckmann T; Schumacher U; Clauditz TS; Betz CS; Petersen C; Rothkamm K; Münscher A; Kriegs M
Int J Cancer; 2021 Sep; 149(5):1166-1180. PubMed ID: 33890294
[TBL] [Abstract][Full Text] [Related]
56. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
57. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
[TBL] [Abstract][Full Text] [Related]
58. Src family kinase-independent signal transduction and gene induction by leukemia inhibitory factor.
Laszlo GS; Nathanson NM
J Biol Chem; 2003 Jul; 278(30):27750-7. PubMed ID: 12764151
[TBL] [Abstract][Full Text] [Related]
59. The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets.
Canobbio I; Cipolla L; Guidetti GF; Manganaro D; Visconte C; Kim S; Okigaki M; Falasca M; Kunapuli SP; Torti M
Biochem J; 2015 Jul; 469(2):199-210. PubMed ID: 25967238
[TBL] [Abstract][Full Text] [Related]
60. The Src signaling pathway: a potential target in melanoma and other malignancies.
Homsi J; Cubitt C; Daud A
Expert Opin Ther Targets; 2007 Jan; 11(1):91-100. PubMed ID: 17150037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
